BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture

Stock Information for BioSig Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.